Who are 99mTc-Etarfolatide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tomudex, Pemetrexe, Pluvicto, LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN, Pluvicto, 177Lu-PSMA-617.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/99mtc-etarfolatide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

99mTc-Etarfolatide — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

99mTc-Etarfolatide (99mTc-Etarfolatide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: radioligand. Area: Oncology.

phase 1 radioligand folate receptor beta Oncology Small molecule Live · refreshed every 30 min

Target snapshot

99mTc-Etarfolatide (99mTc-Etarfolatide) — Endocyte. binds to folate receptor beta

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
99mTc-Etarfolatide TARGET	99mTc-Etarfolatide	Endocyte	phase 1	radioligand	folate receptor beta
Tomudex	RALTITREXED		marketed	raltitrexed	Folate receptor beta, Folate transporter 1, Proton-coupled folate transporter	1996-01-01
Pemetrexe	Pemetrexe	Rongjie Tao	marketed		Serine hydroxymethyltransferase, cytosolic, Folate receptor beta, Folate transporter 1
Pluvicto	TETRAXETAN	Novartis	marketed	Radioligand Therapeutic Agent [EPC]		2025-01-01
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN	LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN		marketed	Radioligand Therapeutic Agent [EPC]	PSMA	2022-01-01
Pluvicto	Lutetium (177Lu) vipivotide tetraxetan	Aaa Usa Novartis	marketed	Radioligand Therapeutic Agent [EPC]	Prostate-specific antigen	2022-01-01
177Lu-PSMA-617	177Lu-PSMA-617	European Organisation for Research and Treatment of Cancer - EORTC	phase 3	Radioligand therapy / Targeted radionuclide therapy	PSMA (Prostate-Specific Membrane Antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-08-15 — Pluvicto · 10406240 · US
2028-08-15 — Pluvicto · 11318121 · US
2034-10-17 — Pluvicto · 10398791 · US

Sponsor landscape (radioligand class)

Endocyte · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 99mTc-Etarfolatide — Competitive Intelligence Brief. https://druglandscape.com/ci/99mtc-etarfolatide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing